DURECT Corporation Publishes Promising Larsucosterol Findings for Alcohol-Associated Hepatitis DURECT Corporation has published significant Phase 2b trial data on Larsucosterol, showing promising results for treating Alcohol-Associated Hepatitis.

DURECT Corporation Publishes Promising Larsucosterol Findings for Alcohol-Associated Hepatitis #USA #DURECT #Cupertino #Larsucosterol #AHFIRM_Trial

DURECT Corporation Sells ALZET® Product Line to Lafayette Instrument for $17.5 Million DURECT Corporation has sold its ALZET® line to Lafayette Instrument Co. for $17.5 million, focusing on their primary biopharmaceutical developments.

DURECT Corporation Sells ALZET® Product Line to Lafayette Instrument for $17.5 Million #United_States #Lafayette_Instrument #DURECT #ALZET #Cupertino